leadf
logo-loader
viewBiocept Inc

Biocept reveals double-digit revenue jump and new Target Selector molecular assay kit

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic.

What's more, Nall says the developer of liquid biopsy tests has released a new Target Selector molecular assay research-use-only kit for clients to use in their own laboratories. The kit will help to detect BRAF mutations, among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.

Quick facts: Biocept Inc

Price: 4.46 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $59.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read